New York – September 16, 2026 – Cooley advised Sangamo Therapeutics, a publicly traded genomic medicine company, on the closing of its asset sale transactions with PTC Therapeutics and Eli Lilly and Company as part of its Chapter 11 restructuring.

Introduced this year as the awards’ first law firm category, Deal Adviser of the Year recognizes law firms for their work advising on life sciences transactions and the impact of their advisory teams whose work has significantly contributed to advancing the industry through strategic guidance, innovative solutions, and value creation.

Cooley is representing Sangamo in its Chapter 11 restructuring and complex Section 363 sale process involving the company’s genomic medicine programs, platform technologies and intellectual property. Working on an accelerated timeline, the Cooley team helped structure a competitive sale process that began with Eli Lilly and Astellas Pharma serving as stalking-horse bidders and ultimately resulted in Eli Lilly and PTC Therapeutics emerging as the successful bidders following a court-supervised auction.

The winning bids together provided approximately $161 million in cash consideration at closing, plus up to $100 million in potential future milestone payments. The transactions included the sale of Sangamo’s Fabry disease program, isaralgagene civaparvovec, or ST-920, to PTC and the sale of its capsid delivery, zinc finger, and modular platforms and prion disease program, ST-506, to Eli Lilly.

Lawyers Cullen Speckhart, Marya Postner, Lauren A. Reichardt, Robert Eisenbach, Lindsey O’Crump Crow and Miriam Peguero Medrano led the Cooley team advising Sangamo.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.